JPET xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wardell, J. R.
Right arrow Articles by Fowler, P. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wardell, J. R., Jr.
Right arrow Articles by Fowler, P. J.
Journal of Pharmacology And Experimental Therapeutics, Vol. 189, Issue 1, 167-184, 1974
Copyright © 1974 by American Society for Pharmacology and Experimental Therapeutics


STUDIES ON CARBUTEROL (SK&F 40383-A), A NEW SELECTIVE BRONCHODILATOR AGENT

J. R. Wardell Jr. 1, D. F. Colella 1, A. Shetzline 1, and P. J. Fowler 1

1 Department of Pharmacology, Smith Kline & French Laboratories, Philadelphia, Pennsylvania

Carbuterol—[5-[2-(tert.-butylamino)-1-hydroxyethyl]-2-hydroxyphenyl] urea hydrochloride, SK&F 40383-A—was evaluated for its bronchodilator and cardiovascular actions, mechanism of action and acute toxicity by various routes of administration in several animal species. Comparisons were made with isoproterenol and salbutamol. Carbuterol exhibited potent bronchodilator activity in vitro and in vivo in the cat, dog and guinea pig and, compared with isoproterenol, was much more selective for tracheobronchial smooth muscle than for cardiac muscle. Both the bronchodilator and cardiac activities of carbuterol are apparently mediated through beta adrenergic receptor stimulation. Thus, carbuterol discriminates between the cardiac (beta-1) and tracheobronchial smooth musde (beta-2) receptors proposed by Lands and co-workers (Lands, A. M. and Brown, T. G., Jr. Proc. Soc. Exp. Biol. Med. 116: 331-333, 1964; Lands, A. M., et al. Nature (London) 214: 596-598, 1967, Life Sci. 6: 2241-2249, 1967). Although carbuterol was similar in bronchodilator potency to isoproterenol, its relative vasodepressor potency was much less, thereby demonstrating a further selectivity of action. At equiactive aerosol bronchodilator doses, the duration of action of carbuterol was at least 10 times that of isoproterenol, and its oral bronchodilator activity was also more prolonged. In general, carbuterol was approximately equivalent to salbutamol in bronchodilator potency, duration of action and degree of separation between bronchodilator and cardiovascular-stimulant activity, except that carbuterol exhibited a somewhat greater separation than salbutamol in doses producing bronchodilation and cardiac stimulation after oral administration in conscious guinea pigs. Acute toxicity studies in mice, rats and guinea pigs indicated a wide safety margin for carbuterol. The results demonstrate that carbuterol, administered either orally or by aerosol, is a selective bronchodilator in animals and suggest it to be a potentially useful agent in man.

Submitted on August 14, 1973
Accepted on November 20, 1973







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1974 by the American Society for Pharmacology and Experimental Therapeutics.